- Third quarter 2023 Total Revenue of $28.1 million which includes record
TAVALISSE® net product sales of $24.5 million and REZLIDHIA® net
product sales of $2.7
million
- New data on olutasidenib in mIDH1 relapsed or refractory
acute myeloid leukemia to be presented at ASH Annual
Meeting
- Conference call and webcast scheduled today at 4:30 p.m. Eastern Time
SOUTH
SAN FRANCISCO, Calif., Nov. 7, 2023
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)
today reported financial results for the third quarter ended
September 30, 2023, including sales
of TAVALISSE® (fostamatinib disodium hexahydrate)
tablets for the treatment of adults with chronic immune
thrombocytopenia (ITP) who have had an insufficient response to a
previous treatment and sales of
REZLIDHIA® (olutasidenib) capsules for the
treatment of adult patients with relapsed or refractory (R/R) acute
myeloid leukemia (AML) with a susceptible isocitrate
dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved
test.
"The third quarter of 2023 was marked by strong momentum from
our commercial hematology-oncology portfolio driven by record
TAVALISSE net product sales and growing REZLIDHIA awareness
among leukemia treaters," said Raul
Rodriguez, Rigel's president and CEO. "These strong net
sales combined with our expense discipline have allowed us to make
substantial progress on our plan to reach financial
breakeven."
Business Update
- In the third quarter of 2023, a total of 2,551 bottles of
TAVALISSE were sold in the U.S. During the quarter, 2,412 bottles
were shipped directly to patients and clinics, representing the
highest number of bottles shipped to patients and clinics in a
quarter since launch.
- During the third full quarter of launch, a total of 210 bottles
of REZLIDHIA were sold in the U.S. During this quarter, 221 bottles
were shipped directly to patients and clinics.
- Last week, Rigel announced four poster presentations
highlighting data from the Company's commercial and clinical-stage
hematology-oncology portfolio at the upcoming 65th American Society
of Hematology (ASH) Annual Meeting and Exposition. Included is a
poster, Abstract #2888, reporting post hoc analyses in a subset of
patients with mIDH1 R/R AML or MDS that were R/R to hematopoietic
stem cell transplant (HSCT), ivosidenib (IVO), or venetoclax
(VEN). The analyses suggest
that olutasidenib alone or in combination with azacitidine may
induce complete remissions in these patients. To learn more
about Rigel's clinical and commercial hematology-oncology portfolio
visit Booth #2805 during ASH 2023.
- Rigel continues to advance its open-label, Phase 1b clinical trial of R2891, an
investigational, potent, and selective IRAK1/4 inhibitor, in
patients with lower-risk myeloid dysplastic syndrome (LR-MDS) who
are refractory/resistant to prior therapies. Target enrollment in
the second cohort of the trial has been completed and Rigel is
currently enrolling patients in the third cohort. Preliminary data
results are expected by mid-year 2024.
- In September, the Data and Safety Monitoring Board (DSMB)
recommended that the fostamatinib study arm of the ACTIV-4 Host
Tissue (NECTAR) platform cease enrollment. No safety concerns were
identified. The National Heart, Lung, and Blood Institute (NHLBI),
part of the National Institutes of Health, concurs with the DSMB's
recommendations and has asked the trial investigators to cease
enrollment, complete follow-up for participants already enrolled,
and complete study closeout. The full study data will be analyzed
and disseminated as previously planned.
Financial Update
For the third quarter of 2023, Rigel
reported a net loss of $5.7 million,
or $0.03 per basic and diluted share,
compared to a net loss of $19.0
million, or $0.11 per basic
and diluted share, for the same period of 2022.
For the third quarter of 2023, total revenues were $28.1 million, consisting of $24.5 million in TAVALISSE net product sales,
$2.7 million in REZLIDHIA net product
sales, and $1.0 million in contract
revenues from collaborations. TAVALISSE net product sales of
$24.5 million increased by
$5.3 million, or 27%, compared to
$19.2 million in the same period of
2022. Contract revenues from collaborations for the third quarter
of 2023 consisted primarily of royalty revenue from Grifols S.A.
(Grifols) of $0.8 million.
For the third quarter of 2023, total costs and expenses were
$32.6 million, compared to
$40.8 million for the same period of
2022. The decrease in costs and expenses was partly due to
decreased research and development costs due to the completion of
activities related to the Phase 3 clinical trial of fostamatinib in
wAIHA and the Phase 3 clinical trial of fostamatinib in high-risk
hospitalized patients with COVID-19. Also contributing to the
decrease, were lower facility-related costs and an upfront payment
to Forma Therapeutics Inc. (Forma, now Novo Nordisk) recorded as
in-process research and development (IPR&D) and included within
cost and expenses in the third quarter of 2022. These decreases
were partially offset by increased research and development costs
due to the timing of activities related to the IRAK 1/4 inhibitor
program.
For the nine months ended September 30,
2023, Rigel reported a net loss of $25.8 million, or $0.15 per basic and diluted share, compared to a
net loss of $60.0 million, or
$0.35 per basic and diluted share,
for the same period of 2022.
For the nine months ended September 30,
2023, total revenues were $81.1
million, consisting of $68.1
million in TAVALISSE net product sales, $6.7 million in REZLIDHIA net product sales,
$5.3 million in contract revenues
from collaborations, and $1.0 million
in government contract revenue. TAVALISSE net product sales of
$68.1 million increased by
$14.1 million, or 26%, compared to
$53.9 million in the same period of
2022. Contract revenues from collaborations for the nine months
ended September 30, 2023, consisted
primarily of revenue from Grifols related to the delivery of drug
supplies of $2.8 million and a
royalty of $2.3 million. Government
contract revenue for the nine months ended September 30, 2023, was related to income
recognized in the second quarter of 2023 pursuant to the agreement
with the U.S. Department of Defense to support Rigel's Phase 3
clinical trial of fostamatinib in high-risk hospitalized patients
with COVID-19.
For the nine months ended September 30,
2023, total costs and expenses were $103.5 million, compared to $126.6 million for the same period of 2022. The
decrease in costs and expenses was partly due to decreased research
and development costs due to the completion of trial activities
related to the Phase 3 clinical trial of fostamatinib in wAIHA and
the Phase 3 clinical trial of fostamatinib in high-risk
hospitalized patients with COVID-19, as well as timing of
activities related to the IRAK 1/4 inhibitor program. Also
contributing to the decrease were lower facility-related costs, and
an upfront payment to Forma (now Novo Nordisk) recorded as
IPR&D and included within cost and expenses in the third
quarter of 2022.
As of September 30, 2023, Rigel
had cash, cash equivalents and short-term investments of
$62.4 million, compared to
$58.2 million as of December 31, 2022.
Conference Call and Webcast with Slides Today at 4:30pm Eastern Time
Rigel will hold a live
conference call and webcast today at 4:30pm
Eastern Time (1:30pm Pacific
Time).
Participants can access the live conference call by dialing
(877) 407-3088 (domestic) or (201) 389-0927 (international). The
conference call will also be webcast live and can be accessed from
the Investor Relations section of the company's website at
www.rigel.com. The webcast will be archived and available for
replay after the call via the Rigel website.
About ITP
In patients with ITP (immune
thrombocytopenia), the immune system attacks and destroys the
body's own blood platelets, which play an active role in blood
clotting and healing. Common symptoms of ITP are excessive bruising
and bleeding. People suffering with chronic ITP may live with an
increased risk of severe bleeding events that can result in serious
medical complications or even death. Current therapies for ITP
include steroids, blood platelet production boosters (TPO-RAs), and
splenectomy. However, not all patients respond to existing
therapies. As a result, there remains a significant medical need
for additional treatment options for patients with ITP.
About AML
Acute myeloid leukemia (AML) is a rapidly
progressing cancer of the blood and bone marrow that affects
myeloid cells, which normally develop into various types of mature
blood cells. AML occurs primarily in adults and accounts for about
1 percent of all adult cancers. The American Cancer Society
estimates that in the United
States alone, there will be about 20,380 new cases, most in
adults, in 2023.2
Relapsed AML affects about half of all patients who, following
treatment and remission, experience a return of leukemia cells in
the bone marrow.3 Refractory AML, which affects
between 10 and 40 percent of newly diagnosed patients, occurs when
a patient fails to achieve remission even after intensive
treatment.4 Quality of life declines for patients
with each successive line of treatment for AML, and well-tolerated
treatments in relapsed or refractory disease remain an unmet
need.
About R289
R289 is a prodrug of R835, an IRAK1/4 dual inhibitor, which
has been shown in preclinical studies to block inflammatory
cytokine production in response to toll-like receptor (TLR) and
interleukin-1 receptor (IL-1R) family signaling. TLRs and IL-1Rs
play a critical role in the innate immune response and
dysregulation of these pathways can lead to various inflammatory
conditions. Chronic stimulation of both these receptor systems is
thought to cause the pro-inflammatory environment in the bone
marrow responsible for persistent cytopenias in lower-risk MDS
patients.5
About
TAVALISSE®
Indication
TAVALISSE
(fostamatinib disodium hexahydrate) tablets is indicated for the
treatment of thrombocytopenia in adult patients with chronic immune
thrombocytopenia (ITP) who have had an insufficient response to a
previous treatment.
Important Safety Information
Warnings and
Precautions
- Hypertension can occur with TAVALISSE treatment. Patients with
pre-existing hypertension may be more susceptible to the
hypertensive effects. Monitor blood pressure every 2 weeks until
stable, then monthly, and adjust or initiate antihypertensive
therapy for blood pressure control maintenance during therapy. If
increased blood pressure persists, TAVALISSE interruption,
reduction, or discontinuation may be required.
- Elevated liver function tests (LFTs), mainly ALT and AST, can
occur with TAVALISSE. Monitor LFTs monthly during treatment. If ALT
or AST increase to ≥3 x upper limit of normal, manage
hepatotoxicity using TAVALISSE interruption, reduction, or
discontinuation.
- Diarrhea occurred in 31% of patients and severe diarrhea
occurred in 1% of patients treated with TAVALISSE. Monitor patients
for the development of diarrhea and manage using supportive care
measures early after the onset of symptoms. If diarrhea becomes
severe (≥Grade 3), interrupt, reduce dose or discontinue
TAVALISSE.
- Neutropenia occurred in 6% of patients treated with TAVALISSE;
febrile neutropenia occurred in 1% of patients. Monitor the ANC
monthly and for infection during treatment. Manage toxicity with
TAVALISSE interruption, reduction, or discontinuation.
- TAVALISSE can cause fetal harm when administered to pregnant
women. Advise pregnant women the potential risk to a fetus. Advise
females of reproductive potential to use effective contraception
during treatment and for at least 1 month after the last dose.
Verify pregnancy status prior to initiating TAVALISSE. It is
unknown if TAVALISSE or its metabolite is present in human milk.
Because of the potential for serious adverse reactions in a
breastfed child, advise a lactating woman not to breastfeed during
TAVALISSE treatment and for at least 1 month after the last
dose.
Drug Interactions
- Concomitant use of TAVALISSE with strong CYP3A4 inhibitors
increases exposure to the major active metabolite of TAVALISSE
(R406), which may increase the risk of adverse reactions. Monitor
for toxicities that may require a reduction in TAVALISSE dose.
- It is not recommended to use TAVALISSE with strong CYP3A4
inducers, as concomitant use reduces exposure to R406.
- Concomitant use of TAVALISSE may increase concentrations of
some CYP3A4 substrate drugs and may require a dose reduction of the
CYP3A4 substrate drug.
- Concomitant use of TAVALISSE may increase concentrations of
BCRP substrate drugs (eg, rosuvastatin) and P-Glycoprotein (P-gp)
substrate drugs (eg, digoxin), which may require a dose reduction
of the BCRP and P-gp substrate drug.
Adverse Reactions
- Serious adverse drug reactions in the ITP double-blind studies
were febrile neutropenia, diarrhea, pneumonia, and hypertensive
crisis, which occurred in 1% of TAVALISSE patients. In addition,
severe adverse reactions occurred including dyspnea and
hypertension (both 2%), neutropenia, arthralgia, chest pain,
diarrhea, dizziness, nephrolithiasis, pain in extremity, toothache,
syncope, and hypoxia (all 1%).
- Common adverse reactions (≥5% and more common than placebo)
from FIT-1 and FIT-2 included: diarrhea, hypertension, nausea,
dizziness, ALT and AST increased, respiratory infection, rash,
abdominal pain, fatigue, chest pain, and neutropenia.
Please see www.TAVALISSEUSPI.com for Full Prescribing
Information.
To report side effects of prescription drugs to the FDA,
visit www.fda.gov/medwatch or call 1-800-FDA-1088
(800-332-1088).
TAVALISSE is a registered trademark of Rigel Pharmaceuticals,
Inc.
About
REZLIDHIA®
INDICATION
REZLIDHIA
is indicated for the treatment of adult patients with relapsed or
refractory acute myeloid leukemia (AML) with a susceptible
isocitrate dehydrogenase-1 (IDH1) mutation as detected by an
FDA-approved test.
IMPORTANT SAFETY INFORMATION
WARNING:
DIFFERENTIATION SYNDROME Differentiation syndrome, which
can be fatal, can occur with REZLIDHIA treatment. Symptoms may
include dyspnea, pulmonary infiltrates/pleuropericardial effusion,
kidney injury, hypotension, fever, and weight gain. If
differentiation syndrome is suspected, withhold REZLIDHIA and
initiate treatment with corticosteroids and hemodynamic monitoring
until symptom resolution.
|
WARNINGS AND PRECAUTIONS
Differentiation
Syndrome
REZLIDHIA can cause differentiation syndrome. In
the clinical trial of REZLIDHIA in patients with relapsed or
refractory AML, differentiation syndrome occurred in 16% of
patients, with grade 3 or 4 differentiation syndrome occurring in
8% of patients treated, and fatalities in 1% of patients.
Differentiation syndrome is associated with rapid proliferation and
differentiation of myeloid cells and may be life-threatening or
fatal. Symptoms of differentiation syndrome in patients treated
with REZLIDHIA included leukocytosis, dyspnea, pulmonary
infiltrates/pleuropericardial effusion, kidney injury, fever,
edema, pyrexia, and weight gain. Of the 25 patients who experienced
differentiation syndrome, 19 (76%) recovered after treatment or
after dose interruption of REZLIDHIA. Differentiation syndrome
occurred as early as 1 day and up to 18 months after REZLIDHIA
initiation and has been observed with or without concomitant
leukocytosis.
If differentiation syndrome is suspected, temporarily withhold
REZLIDHIA and initiate systemic corticosteroids (e.g.,
dexamethasone 10 mg IV every 12 hours) for a minimum of 3 days and
until resolution of signs and symptoms. If concomitant
leukocytosis is observed, initiate treatment with hydroxyurea, as
clinically indicated. Taper corticosteroids and hydroxyurea after
resolution of symptoms. Differentiation syndrome may recur with
premature discontinuation of corticosteroids and/or hydroxyurea
treatment. Institute supportive measures and hemodynamic monitoring
until improvement; withhold dose of REZLIDHIA and consider dose
reduction based on recurrence.
Hepatotoxicity
REZLIDHIA can cause hepatotoxicity,
presenting as increased alanine aminotransferase (ALT), increased
aspartate aminotransferase (AST), increased blood alkaline
phosphatase, and/or elevated bilirubin. Of 153 patients with
relapsed or refractory AML who received REZLIDHIA, hepatotoxicity
occurred in 23% of patients; 13% experienced grade 3 or 4
hepatotoxicity. One patient treated with REZLIDHIA in combination
with azacitidine in the clinical trial, a combination for which
REZLIDHIA is not indicated, died from complications of drug-induced
liver injury. The median time to onset of hepatotoxicity in
patients with relapsed or refractory AML treated with REZLIDHIA was
1.2 months (range: 1 day to 17.5 months) after REZLIDHIA
initiation, and the median time to resolution was 12 days (range: 1
day to 17 months). The most common hepatotoxicities were elevations
of ALT, AST, blood alkaline phosphatase, and blood bilirubin.
Monitor patients frequently for clinical symptoms of hepatic
dysfunction such as fatigue, anorexia, right upper abdominal
discomfort, dark urine, or jaundice. Obtain baseline liver function
tests prior to initiation of REZLIDHIA, at least once weekly for
the first two months, once every other week for the third month,
once in the fourth month, and once every other month for the
duration of therapy. If hepatic dysfunction occurs, withhold,
reduce, or permanently discontinue REZLIDHIA based on
recurrence/severity.
ADVERSE REACTIONS
The most common (≥20%) adverse
reactions, including laboratory abnormalities, were aspartate
aminotransferase increased, alanine aminotransferase increased,
potassium decreased, sodium decreased, alkaline phosphatase
increased, nausea, creatinine increased, fatigue/malaise,
arthralgia, constipation, lymphocytes increased, bilirubin
increased, leukocytosis, uric acid increased, dyspnea, pyrexia,
rash, lipase increased, mucositis, diarrhea and transaminitis.
DRUG INTERACTIONS
- Avoid concomitant use of REZLIDHIA with strong or moderate
CYP3A inducers.
- Avoid concomitant use of REZLIDHIA with sensitive CYP3A
substrates unless otherwise instructed in the substrates
prescribing information. If concomitant use is unavoidable, monitor
patients for loss of therapeutic effect of these drugs.
LACTATION
Advise women not to breastfeed during
treatment with REZLIDHIA and for 2 weeks after the last dose.
GERIATRIC USE
No overall differences in effectiveness
were observed between patients 65 years and older and younger
patients. Compared to patients younger than 65 years of age, an
increase in incidence of hepatotoxicity and hypertension was
observed in patients ≥65 years of age.
HEPATIC IMPAIRMENT
In patients with mild or moderate
hepatic impairment, closely monitor for increased probability of
differentiation syndrome.
Click here for Full Prescribing Information,
including Boxed WARNING.
To report side effects of prescription drugs to the FDA, visit
www.fda.gov/medwatch or call 1-800-FDA-1088 (800-332-1088).
REZLIDHIA is a registered trademark of Rigel Pharmaceuticals,
Inc.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)
is a biotechnology company dedicated to discovering, developing and
providing novel therapies that significantly improve the lives of
patients with hematologic disorders and cancer. Founded in 1996,
Rigel is based in South San Francisco,
California. For more information on Rigel, the Company's
marketed products and pipeline of potential products, visit
www.rigel.com.
- R289 is an investigational compound not approved by the
FDA.
- The American Cancer Society. Key Statistics for Acute Myeloid
Leukemia (AML). Revised January 12,
2023. Accessed Feb. 15, 2023:
https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html
- Leukaemia Care. Relapse in Acute Myeloid Leukaemia (AML).
Version 3. Reviewed October 2021.
Accessed Feb 15, 2023:
https://media.leukaemiacare.org.uk/wp-content/uploads/Relapse-in-Acute-Myeloid-Leukaemia-AML-Web-Version.pdf
- Thol F, Schlenk RF, Heuser M, Ganser A. How I treat
refractory and early relapsed acute myeloid leukemia. Blood
(2015) 126 (3): 319-27. doi:
https://doi.org/10.1182/blood-2014-10-551911
- Sallman DA et al. Unraveling the Pathogenesis of MDS:
The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype.
Front Oncol. June 16, 2016.
DOI: https://doi.org/10.3389/fonc.2016.0015
Forward Looking Statements
This press release
contains forward-looking statements relating to, among other
things, the potential and market opportunity of olutasidenib as
therapeutics for R/R AML and other conditions, the
commercialization of fostamatinib or olutasidenib in the U.S. and
international markets, and Rigel's ability to further develop its
clinical stage and early-stage product candidates and Rigel's
partnering effort, including the progress of Phase 1b clinical trial of R289 for the treatment of
lower-risk myeloid dysplastic syndrome. Any statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Forward-looking
statements can be identified by words such as "plan", "potential",
"may", "expects", "will" and similar expressions in reference to
future periods. Forward-looking statements are neither historical
facts nor assurances of future performance. Instead, they are based
on Rigel's current beliefs, expectations, and assumptions and hence
they inherently involve significant risks,
uncertainties and changes in circumstances that are
difficult to predict and many of which are outside of our
control. Therefore, you should not rely on any of these
forward-looking statements. Actual results and the timing of events
could differ materially from those anticipated in such forward
looking statements as a result of these risks and uncertainties,
which include, without limitation, risks and uncertainties
associated with the commercialization and marketing of fostamatinib
or olutasidenib; risks that the FDA, European Medicines Agency,
PMDA or other regulatory authorities may make adverse decisions
regarding fostamatinib or olutasidenib; risks that clinical trials
may not be predictive of real-world results or of results in
subsequent clinical trials; risks that fostamatinib or olutasidenib
may have unintended side effects, adverse reactions or incidents of
misuses; the availability of resources to develop Rigel's product
candidates; market competition; as well as other risks detailed
from time to time in Rigel's reports filed with the Securities and
Exchange Commission, including its Quarterly Report on Form 10-Q
for the quarter ended June 30, 2023
and subsequent filings. Any forward-looking statement made by us in
this press release is based only on information
currently available to us and speaks only as of the date on which
it is made. Rigel does not undertake any obligation to update
forward-looking statements, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise, and expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein,
except as required by law.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David
Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
RIGEL
PHARMACEUTICALS, INC.
|
STATEMENTS OF
OPERATIONS
|
(in thousands,
except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30,
|
|
Nine Months Ended
September 30,
|
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
|
(unaudited)
|
Revenues:
|
|
|
|
|
|
|
|
|
Product sales,
net
|
$
27,129
|
|
$
19,188
|
|
$
74,755
|
|
$
53,935
|
|
Contract revenues from
collaborations
|
1,005
|
|
722
|
|
5,335
|
|
12,529
|
|
Government
contract
|
-
|
|
2,500
|
|
1,000
|
|
2,500
|
|
Total
revenues
|
28,134
|
|
22,410
|
|
81,090
|
|
68,964
|
Costs and
expenses:
|
|
|
|
|
|
|
|
|
Cost of product
sales
|
1,268
|
|
250
|
|
3,320
|
|
1,407
|
|
Research and
development (see Note A)
|
6,475
|
|
14,666
|
|
21,336
|
|
44,907
|
|
Selling, general and
administrative (see Note A)
|
24,856
|
|
25,897
|
|
78,891
|
|
80,279
|
|
Total costs and
expenses
|
32,599
|
|
40,813
|
|
103,547
|
|
126,593
|
Loss from
operations
|
(4,465)
|
|
(18,403)
|
|
(22,457)
|
|
(57,629)
|
|
Interest
income
|
672
|
|
192
|
|
1,594
|
|
255
|
|
Interest
expense
|
(1,899)
|
|
(826)
|
|
(4,965)
|
|
(2,600)
|
Net
loss
|
$
(5,692)
|
|
$
(19,037)
|
|
$
(25,828)
|
|
$
(59,974)
|
|
|
|
|
|
|
|
|
|
Net loss per share,
basic and diluted
|
$
(0.03)
|
|
$
(0.11)
|
|
$
(0.15)
|
|
$
(0.35)
|
|
|
|
|
|
|
|
|
|
Weighted average shares
used in computing net loss per share, basic and diluted
|
174,364
|
|
172,836
|
|
173,897
|
|
172,256
|
|
|
|
|
|
|
|
|
|
Note
A
|
|
|
|
|
|
|
|
Stock-based
compensation expense included in:
|
|
|
|
|
|
|
|
|
Selling, general and
administrative
|
$
1,596
|
|
$
2,119
|
|
$
5,127
|
|
$
6,791
|
|
Research and
development
|
347
|
|
588
|
|
1,746
|
|
1,514
|
|
|
$
1,943
|
|
$
2,707
|
|
$
6,873
|
|
$
8,305
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUMMARY BALANCE
SHEET DATA
|
(in
thousands)
|
|
|
|
|
|
|
|
|
|
|
|
As
of
|
|
|
|
|
|
|
September 30,
2023
|
|
December 31,
2022 (1)
|
|
|
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
Cash, cash equivalents
and short-term investments
|
$
62,351
|
|
$
58,206
|
|
|
|
|
Total
assets
|
115,324
|
|
134,279
|
|
|
|
|
Stockholders'
deficit
|
(31,834)
|
|
(13,616)
|
|
|
|
|
(1)
|
Derived from audited
financial statements
|
|
|
|
|
|
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-reports-third-quarter-2023-financial-results-and-provides-business-update-301980485.html
SOURCE Rigel Pharmaceuticals, Inc.